Meeting Program
 |
To view program in "24 hour" time (international) click here. |
| Sunday, February 14 | ||
|---|---|---|
| 3:00 - 7:30 PM | Registration | Promenade |
| 6:30 - 7:30 PM | Refreshments | Promenade |
| 7:30 - 8:30 PM |
Keynote Address Registered attendees for this meeting can view Abstracts for this session starting on 01/14/2010 |
Mesa A-B |
|
*
Gerry Wright,
McMaster University, Canada
|
||
|
Patrice Courvalin,
Institut Pasteur, France
Evolution and Dissemination of Antibiotic Resistance: The Glycopeptide Model |
||
| Monday, February 15 | ||
| 7:00 - 8:00 AM | Breakfast | Chamisa |
| 8:00 - 11:00 AM |
The Problem of Antibiotic Resistance and the Need for New Drugs Registered attendees for this meeting can view Abstracts for this session starting on 01/14/2010 |
Mesa A-B |
|
*
Julian Davies,
University of British Columbia, Canada
|
||
|
Donald E. Low,
Mount Sinai Hospital, Canada
Bacterial Pathogens in the Clinics and Community: The need for New Antibiotics |
||
|
Valerie Mizrahi,
University of the Witwatersrand - MMRU, South Africa
New Tools for Tuberculosis Drug Discovery: Development of Novel Screening Strains of Mycobacterium tuberculosis and Application in Target-Based Approaches |
||
|
Michael G. Surette,
University of Calgary, Canada
The Clinical Challenge of Microbial Communities |
||
|
Gerry Wright,
McMaster University, Canada
Antibiotic Resistance: Where Does it Come from and What Can We Do About it? |
||
| 9:20 - 9:40 AM | Coffee Break | Promenade |
| 11:00 AM- | On Own for Lunch and Recreation | |
| 11:00 AM- 1:00 PM | Poster Setup | Mesa C/Chamisa |
| 1:00 - 10:00 PM | Poster Viewing | Mesa C/Chamisa |
| 4:30 - 5:00 PM | Coffee Available | Promenade |
| 5:00 - 7:00 PM |
Success and Barriers in Modern Antibacterial Drug Discovery Registered attendees for this meeting can view Abstracts for this session starting on 01/14/2010 |
Mesa A-B |
|
*
Stewart L. Fisher,
AstraZeneca R&D Boston, USA
|
||
|
Julian Davies,
University of British Columbia, Canada
Where will New Antibiotics Come From? |
||
|
Mike Barbachyn,
AstraZeneca Pharmaceuticals LP, USA
The Natural History of the Oxazolidinones |
||
|
Patricia Bradford,
Novartis Institutes for BioMedical Research, USA
Difficulties and Success in Bringing the 3rd Generation Tetracyclines to Market |
||
| 7:00 - 8:00 PM | Social Hour w/ Lite Bites | Chamisa |
| 7:30 - 10:00 PM |
Poster Session 1 Registered attendees for this meeting can view Abstracts for this session starting on 01/14/2010 |
Mesa C/Chamisa |
| Tuesday, February 16 | ||
| 7:00 - 8:00 AM | Breakfast | Chamisa |
| 8:00 - 11:00 AM |
Mining Known Pathways as Targets for New Antibiotics Registered attendees for this meeting can view Abstracts for this session starting on 01/14/2010 |
Mesa A-B |
|
*
Deborah Hung,
Massachusetts General Hospital, USA
|
||
|
Stewart L. Fisher,
AstraZeneca R&D Boston, USA
DNA Replication: Opportunities and Challenges |
||
|
Suzanne Walker,
Harvard Medical School, USA
New Targets for Antibiotics |
||
|
Peter J. Tonge,
Stony Brook University, USA
Slow Onset Inhibitors of Bacterial Fatty Acid Biosynthesis: Residence Time, in Vivo Activity and in Vivo Imaging |
||
|
Thomas A. Steitz,
Howard Hughes Medical Institute, Yale University, USA
From the Structures of Ribosome-Antibiotic Complexes to New Antibiotics |
||
|
Ronald W. Woodard,
University of Michigan, USA
Short Talk: HTS Assay Developments in the KDO Pathway |
||
| 9:20 - 9:40 AM | Coffee Break | Promenade |
| 11:00 AM- | On Own for Lunch and Recreation | |
| 11:00 AM- 1:00 PM | Poster Setup | Mesa C/Chamisa |
| 1:00 - 10:00 PM | Poster Viewing | Mesa C/Chamisa |
| 4:30 - 5:00 PM | Coffee Available | Promenade |
| 5:00 - 7:00 PM |
New Molecules for New (and Old) Challenges Registered attendees for this meeting can view Abstracts for this session starting on 01/14/2010 |
Mesa A-B |
|
*
Eric D. Brown,
McMaster University, Canada
|
||
|
Christopher T. Walsh,
Harvard Medical School, USA
Posttranslational Maturation of Thiazolyl Peptide Antibiotics |
||
|
Mark J. Macielag,
Johnson & Johnson Pharmaceutical Research & Development, USA
What Makes a Good Antibiotic? The Chemistry Perspective. |
||
|
Chris Abell,
University of Cambridge, UK
Application of Fragment-Based Approaches to the Discovery of New Agents Against Mycobacterium tuberculosis |
||
|
Mervyn Bibb,
John Innes Centre, UK
Short Talk: Actinomycete Lantibiotics: An Untapped Clinical Resource? |
||
| 7:00 - 8:00 PM | Social Hour w/ Lite Bites | Chamisa |
| 7:30 - 10:00 PM |
Poster Session 2 Registered attendees for this meeting can view Abstracts for this session starting on 01/14/2010 |
Mesa C/Chamisa |
| Wednesday, February 17 | ||
| 7:00 - 8:00 AM | Breakfast | Chamisa |
| 8:00 - 11:00 AM |
New Antibiotic Targets - Virulence and Quorum Sensing Registered attendees for this meeting can view Abstracts for this session starting on 01/14/2010 |
Mesa A-B |
|
*
Michael G. Surette,
University of Calgary, Canada
|
||
|
Robert E.W. Hancock,
University of British Columbia, Canada
Modulation of Host Immunity as an Anti-Infective Strategy |
||
|
Helen E. Blackwell,
University of Wisconsin-Madison, USA
Expanding the Language of Bacterial Quorum Sensing using Synthetic Ligands |
||
|
Vincent T. Lee,
University of Maryland, USA
Are Type 3 Secretion Systems Good Targets for Antimicrobials? |
||
|
Scott Hultgren,
Washington University School of Medicine, USA
Bacterial Adhesion and Biofilm Formation - A Source of Alternate Antibiotic Targets |
||
| 9:20 - 9:40 AM | Coffee Break | Promenade |
| 11:00 AM- | On Own for Lunch and Recreation | |
| 4:30 - 5:00 PM | Coffee Available | Promenade |
| 5:00 - 7:00 PM |
New Technology - Systems and Synthetic Biology Registered attendees for this meeting can view Abstracts for this session starting on 01/14/2010 |
Mesa A-B |
|
*
Deborah Hung,
Massachusetts General Hospital, USA
|
||
|
Michael Tyers,
University of Edinburgh, UK
Interrogation of the Genetic Landscape with Small Molecules |
||
|
Eric D. Brown,
McMaster University, Canada
Chemical Genomics: Charting Chemical-Genetic Interactions in Bacteria |
||
|
Frederick M. Ausubel,
Massachusetts General Hospital, USA
Whole Organism Antibiotic Screening in C. elegans |
||
| 7:00 - 8:00 PM | Social Hour w/ Lite Bites | Chamisa |
| Thursday, February 18 | ||
| 7:00 - 8:00 AM | Breakfast | Chamisa |
| 8:00 - 11:00 AM |
New Technology - Real Time Diagnostics and Narrow vs. Broad Spectrum Agents Registered attendees for this meeting can view Abstracts for this session starting on 01/14/2010 |
Mesa A-B |
|
*
Gerry Wright,
McMaster University, Canada
|
||
|
Sylvie Garneau-Tsodikova,
University of Michigan, USA
Turning an Aminoglycoside Resistance Problem into a Solution: New Approaches to Chemoenzymatic Synthesis of Antibiotics |
||
|
Roy Kishony,
Harvard Medical School, USA
Inverting the Selective Advantage of Antibiotic Resistance |
||
|
Jose Miguel Trevejo,
Draper Laboratory/Beth Isreal Deaconess Boston, USA
Novel Sensors and Diagnostics for Rapid Identification of Microbial Resistance |
||
|
Vincent A. Fischetti,
Rockefeller University, USA
Using What Phage Have Learned to Kill Gram-Positive Bacteria |
||
| 9:20 - 9:40 AM | Coffee Break | Promenade |
| 11:00 AM- | On Own for Lunch and Recreation | |
| 2:30 - 4:30 PM |
Workshop: Submitted Papers |
Mesa A-B |
|
*
Stewart L. Fisher,
AstraZeneca R&D Boston, USA
|
||
|
Bart Staker,
deCODE biostructures, USA
Ligand Screening at the Seattle Structural Genomics Center for Infectious Disease (SSGCID) |
||
|
Aileen Rubio,
Cubist Pharmaceuticals, USA
Frequency and Distribution of Mutations in mprF in Daptomycin Nonsusceptible Staphylococcus aureus Clinical Isolates |
||
|
Adriana Renzoni,
University Hospital and Medical School of Geneva, Switzerland
Total Genome Sequencing and Complete Genetic Analysis of all SNP-Linked Phenotypes Reveals Novel Clues to the Emergence of Low Level Glycopeptide Intermediate Resistance in Staphylococcus aureus |
||
|
Terence I. Moy,
Cubist Pharmaceuticals, USA
High Rates of Resistance to Three Classes of RNA Polymerase Inhibitors in Staphylococcus aureus |
||
|
Donald T. Moir,
Microbiotix, Inc., USA
Characterization of a Stereo-Specific Class of Inhibitors of Type-Three Secretion |
||
|
M. R. K. Dickon Alley,
Anacor Pharmaceuticals Inc, USA
Structure-Guided Discovery of ABX a 3-Aminomethyl Benzoxaborole: A First in Class Antibacterial for Gram-Negative Bacterial Infections |
||
| 4:30 - 5:00 PM | Coffee Available | Promenade |
| 5:00 - 7:00 PM |
What about the Host? Registered attendees for this meeting can view Abstracts for this session starting on 01/14/2010 |
Mesa A-B |
|
*
Stewart L. Fisher,
AstraZeneca R&D Boston, USA
|
||
|
Deborah Hung,
Massachusetts General Hospital, USA
Antivirulence Therapy |
||
|
David A. Relman,
Stanford University, USA
The Microbiome: Antibiotic Perturbation, Response, and Human Health |
||
|
Dana Philpott,
University of Toronto, Canada
The Nod Pathway as a Novel Target for Anti-Infectives |
||
| 8:00 - 9:00 PM | Social Hour w/ Lite Bites | Mesa Ballroom |
| 8:00 - 11:00 PM | Entertainment | Mesa Ballroom |
| Friday, February 19 | ||
| Departure | ||
| *=Session Chair †=Speaker invited, not yet responded. | ||
Keystone Symposia would like to thank the sponsor of this meeting for their generous support:
We gratefully acknowledge additional support for this conference from:
|
AstraZeneca R&D Boston |
|
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. |
We gratefully acknowledge the generous grant for this conference provided by:
National Institutes of Health
National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI085733-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We gratefully acknowledge the organizations that provide Keystone Symposia with additional support, such as marketing and advertising...
Click here to view these companies